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SUMMARY  Neurofibromatoses are genetic disorders of the nervous 
system that primarily affect the development and growth of neural (nerve) 
cell tissues. These disorders cause tumors to grow on nerves, and produce 
other abnormalities such as skin changes and bone deformities. Although 
many affected persons inherit the disorder, between 30 and 50 percent of 
new cases arise spontaneously through mutation in the individual’s genes. 
We report on seven cases of type 1 neurofibromatosis (NF1) diagnosed 
from 2001 to 2006 at our Department. There were four female and three 
male patients, mean age 46.1 and 49 years, respectively. All patients 
showed neurofibromas accompanied by fibromas, café au lait spots, 
cases showed five axillary freckling (lentigines) and one case showed 
five plexiform neurofibromas and pruritus belonging to NF1 category. All 
patients had affected first degree relatives. Systemic findings were rare 
and included optic glioma in one case and Lisch hamartoma nodules 
in three cases. In all cases, the diagnosis was established according 
to the National Institutes of Health criteria, including at least two of the 
diagnostic criteria for NF1 diagnosis. None of our cases had malignancies 
or gastrointestinal tract involvement.   
KEY WORDS: neurofibroma; neurofibromatosis; Recklinghausen’s 
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INTRODUCTION
 Neurofibromatoses are genetic disorders of 
the nervous system that primarily affect the devel-
opment and growth of neural cell tissues. These 
disorders cause tumors to grow on nerves, and 
produce other abnormalities such as skin chang-
es and bone deformities. Although many affected 
persons inherit the disorder, between 30 and 50 
percent of new cases arise spontaneously through 
mutation  in the individual’s genes. Once this 
change has taken place, the mutant gene can be 
passed onto succeeding generations. The follow-
ing types of neurofibromatosis are distinguished: 
type 1 neurofibromatosis, central neurofibromato-
ses, and neurofibromatosis with café au lait mac-
ules only (1).
 Neurofibromatosis 1 
 Neurofibromatosis 1 (NF1) or von Reckling-
hausen’s disease is a hereditary hamartoma-
tosis, transmitted by an autosomal dominant 
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mechanism. It primarily affects cells of the neural 
crest origin and results in developmental, pigmen-
tary and neoplastic abnormalities (2). It affects 
both sexes with equal frequency (1:3,000). 
 The responsible gene is transmitted with pen-
etrance and is located in the centromeric region 
of chromosome 17 (17q11.2). At least 20 different 
mutations of this gene and relative clinical variants 
have been reported although there are no avail-
able laboratory tests for diagnosis (3). Cutaneous 
findings are café au lait macules, axillary freck-
lings, neurofibromas, plexiform neurofibroma, pig-
mentation, pruritus, juvenile xanthogranulomas, 
lipomas, and angiolipomas.  The severity of cuta-
neous involvement in NF1 is not an indicator of the 
extent of the disease as internal manifestations 
are common and are often more serious. Sys-
temic findings are found in the following organs: 
central nervous system (optic glioma, meningio-
mas, astrocytomas, mental retardation, learning 
disorders), eye (Lisch hamartoma nodules), ear 
(acoustic neuromas), musculoskeletal (scoliosis, 
pseudoarthrosis of long bones, sphenoid dyspla-
sia), endocrine (precocious and delayed puberty, 
pheochromocytoma), and vascular (renovascular 
hypertension, cerebral and gastrointestinal ab-
normal vessels). Neurofibroma is one of the most 
common nerve sheath tumors occurring in the soft 
tissue and generally occurs in NF1. 
 There are basically four types of neurofibromas 
(tumors consisting of Schwann cells and neural fi-
broblasts), found in NF1: 
• cutaneous: superficial, soft button-like tumors 
with no malignant potential; 
• subcutaneous: tumors along the course of sub-
cutaneous peripheral nerves that may cause 
localized pain or tenderness; 
• nodular plexiform: large network of tumors in-
volving dorsal nerve roots; 
• diffuse plexiform: invasive tumors that may in-
volve all layers of the skin, muscle, bone and 
blood vessels.
Neurofibromas may involve spinal nerve roots and 
characteristically grow through an intervertebral 
foramen to produce intraspinal and extraspinal 
masses (dumb-bell tumor). The intraspinal compo-
nent may compress the spinal cord. Cranial nerve 
tumors include optic gliomas, which may produce 
progressive blindness, and acoustic neuromas 
(vestibular schwannoma), which may produce diz-
ziness, ataxia, deafness and tinnitus. The disease 
is usually progressive.
 The diagnostic criteria proposed by the Na-
tional Institutes of Health include at least two of 
the following: (a) 6 or more café au lait skin spots 
greater than 1.5 cm in diameter in the adult or 0.5 
cm in the child; (b) two or more neurofibromas or 
one infiltrating plexiform neurofibroma; (c) axillary 
or inguinal lentigines; (d) ocular glioma; (e) two or 
more Lisch nodules on the anterior surface of the 
iris; (f) a discrete bone lesion or reduced thickness 
of the cortex of long bones with or without pseudo-
arthrosis; and (g) an affected first-degree relative 
(2,4).
 Malignancies can appear in NF1. The two most 
common malignancies are juvenile chronic myelog-
enous leukemia (CML) and malignant schwanno-
ma, the most malignant peripheral nerve sheath 
tumor (MPNST). MPNSTs arise in the deep plexi-
form neurofibromas of NF-1.  They are called neu-
rofibrosarcoma and malignant schwannoma. Most 
tumors in both NF1 and NF2 are benign; however, 
enlargement of a benign tumor can interfere with 
vital functions. It is estimated that a person with 
NF1 has a 3%-15% increased risk of developing. 
The other tumors are rhabdomyosarcoma, Wilms 
tumor, pheochromocytoma, carcinoid tumors, and 
few cases of intestinal leiomyosarcoma and gas-
troparesis (2,5,6). There is no increased incidence 
of malignant melanoma (2).  
 The presence of multiple juvenile xanthogranu-
lomas and neurofibromatosis is a paraneoplastic 
marker of CML (7-10). There is a report on juvenile 
myelomonocytic leukemia in a child with NF1 (7). 
There is also a report on multiple juvenile xantho-
granuloma, CML, and hemophagocytic lympho-
histiocytosis in patients with NF1 (9).
 Although gastrointestinal (GI) tract may be in-
volved in up to one fourth of von Recklingshausen’s 
disease cases, very few reports describe the dis-
ease association with intestinal leiomyosarcoma 
and gastroparesis (11-13). Gastroparesis is a pos-
sible although rare paraneoplastic manifestation. 
Cancers usually associated with gastroparesis as a 
paraneoplastic syndrome are small cell lung carci-
noma and bronchial carcinoid (14,15). However, GI 
tumors such as those of the esophagus, stomach 
and pancreas have also been reported in associa-
tion with this syndrome (16,17). Recently, gastro-
paresis has also been reported in association with 
retroperitoneal leiomyosarcoma (13,18). It has been 
shown that the tumor-induced response may trigger 
a cross-reaction against the cells of the central and 
peripheral nervous system, including those in the 
gut, where an alteration in the plexus of Auerbach 
may be responsible for the GI dysmotility (17).
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Other findings Ocular glioma
1 F 33 15 (2) 2+0+6 Abdomen 3+0+4 None None
2 F 67 Many 2+0+many Plantar, 
trunk 
2 - 5 None Hypertrichosis None
3 M 61 9 (10) ; 
3 (2)
5+0+6 Trunk, face 
and foot
1,5 – 3 Yes None




3+0+6 Yes 17q11.2 gene None
5 M 46 Many (6) 4+0+many Abdomen, 
thigh
3+0+3-6 Some None
6 F 54 Many (3) 6+5+10 Trunk, 
extremities 
5+4+6-7 Some None
7 F 31 Many 
(7x4)
4+ 0+10 Trunk 5+0+4 Three None
Table 1. Clinical characteristics of seven patients with neurofibromatosis type 1
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sin.; Kidney cysts NF1
None None None NF1
None None Grandmother NF1
Yes None Daughter, son Dysrhythmic brain 
lesions 
NF1

















1 F 33 15 (2)
2 F 67 Many
3 M 61 9 (10); 3 (2)
4 M 40 Many (11x7)
5 M 46 Many (6)
6 F 54 Many (3)
7 F 31 Many (7x4)
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 In neurofibromatosis, other manifestations such 
as ataxia, orthostatic hypotension and motor-sen-
sitive peripheral neuropathy are known to be as-
sociated with autoantibodies directed against neu-
ronal components (13,19).
Neurofibromatosis 2 
 Neurofibromatosis 2 (NF2) or central neuro-
fibromatosis is inherited in autosomal dominant 
pattern. The gene is located on chromosome 22q. 
Variable expressivity is much less common than in 
NF1. Clinically, one can find acoustic neuromas, 
mostly bilateral, meningiomas, spinal gliomas, 
café au lait macules, neural tumors (schwanno-
mas, neurofibroma and overlap tumors), hyperpig-
mentation, hairiness, juvenile xanthogranulomas 
with leukemia, and juvenile posterior subcapsular 
cataracts. The ophthalmologist plays an important 
role in making the diagnosis, as several ocular 
manifestations may be shown during childhood, 
before tumors of the central nervous system have 
become symptomatic (20). An early diagnosis of 
NF2 may prevent deafness by early surgical inter-
vention (20). Moreover, as NF2 is a distinct entity 
characterized by bilateral eighth-nerve schwanno-
mas, other intracranial schwannomas and menin-
giomas, and multiple spinal canal schwannomas, 
meningiomas and gliomas screening of the entire 
neural axis is mandatory because of the incidence 
of asymptomatic lesions. Magnetic resonance im-
aging (MRI) is the technique of choice, particularly 
employing contrast-enhanced, T1-weighted se-
quences in multiple image planes.
Treatment
 There is no cure for NF. The main goal of treat-
ment is to monitor its development and intervene 
when necessary. Healthy children with NF should 
be followed-up and examined every 6-12 months 
by a pediatrician. 
 Neurofibromas that become large and painful 
can be cut out to reduce the risk of malignancy 
and other complications. Surgery can help pre-
vent some NF1 bone malformations and remove 
painful or disfiguring tumors; however, there is 
a chance that the tumors may grow back and in 
greater numbers. In the rare instances when tu-
mors become malignant, treatment may include 
surgery, radiation, or chemotherapy.
 Genetic counseling and education about NF 
are important. One concern that should not be 
overlooked is the risk of isolation or loneliness in 
people with NF. People with NF are often anxious 
about future complications, and disfiguring lesions 
may sometimes lead to withdrawal from the soci-
ety. Prenatal diagnosis of familial NF1 or NF2 is 
also possible utilizing amniocentesis or chorionic 
villus sampling procedures.
CASE REPORT
 We report on seven cases of NF1 recorded at 
our Department between 2001 and 2006. There 
were four female and three male patients, mean 
age 46.1 and 49 years, respectively. All cases 
showed neurofibromas accompanied by  fibro-
mas, café au lait spots, while 5 cases showed ax-
illary freckling (lentigines) and one case showed 5 
plexiform neurofibromas and pruritus, all belonging 
to NF1 category (Table 1). All had an early onset of 
NF1 and were treated by surgical intervention for 
numerous neurofibromas. All patients had some 
first degree relatives affected with the disorder. 
The responsible gene for NF1 in the centromeric 
region of chromosome 17 (17q11.2) was proven 
in case 4. The severity of cutaneous involvement 
was similar in six of our patients. Systemic find-
ings were rare and included optic glioma in one 
case and Lisch nodules in three cases. The diag-
nosis was established in all cases according to the 
National Institutes of Health criteria, and included 
at least two of the diagnostic criteria for NF1 di-
agnosis proposed. None of our patients had, and 
there was no gastrointestinal tract involvement.
  
 CONCLUSION
 Although there is no cure for NF, surgical treat-
ment is recommended in all cases with painful 
and large neurofibromas and those with malignant 
alteration. All our cases were followed-up for five 
years and underwent surgical treatment. Until now, 
they are in good condition and free from malignant 
alteration.
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